SEGLENTIS (celecoxib/tramadol)
Self-Administration – oral
Diagnosis considered for coverage:
Indicated for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Coverage Criteria:
For diagnosis of acute pain:
- Dose does not exceed 2 tablets every 12 hours (224 mg/day of celecoxib and 176 mg/day of tramadol); AND
- Patient is 18 years of age or older; AND
- Chart notes document a medical reason why the patient cannot take generic tramadol and generic celecoxib as individual agents; AND
- Patient has tried and failed or has contraindications or intolerance to generic celecoxib and one other prescription strength non-steroidal anti-inflammatory drug; AND
- Patient has tried and failed generic tramadol immediate-release
Reauthorization Criteria:
For diagnosis of acute pain:
- Dose does not exceed 2 tablets every 12 hours (224 mg/day of celecoxib and 176 mg/day of tramadol); AND
- Documentation of a positive clinical response to therapy
Coverage Duration:
- Initial: 1 year
- Reauthorization: 1 year
Authorization is not covered for the following:
The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.
Additional Information:
- Recommended dose: two 56 mg/44 mg tablets every 12 hours as needed for pain
- Contraindicated in:
- All patients younger than 12 years of age
- Post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy
Policy Updates:
- 8/16/2022 – New policy approved by P&T.
References:
- Seglentis Prescribing Information. Kowa Pharmaceuticals America, Inc. Montgomery, Alabama. October 2021.
Last review date: August 16, 2022